- Home
- DYAI vs SCLX Comparison
DYAI vs SCLX Comparison
Compare DYAI & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYAI
- SCLX
- Stock Information
- Founded
- DYAI 1979
- SCLX 2011
- Country
- DYAI United States
- SCLX United States
- Employees
- DYAI N/A
- SCLX N/A
- Industry
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- DYAI Health Care
- SCLX Health Care
- Exchange
- DYAI Nasdaq
- SCLX Nasdaq
- Market Cap
- DYAI 30.2M
- SCLX 35.7M
- IPO Year
- DYAI 2004
- SCLX N/A
- Fundamental
- Price
- DYAI $0.95
- SCLX $18.40
- Analyst Decision
- DYAI Strong Buy
- SCLX Strong Buy
- Analyst Count
- DYAI 1
- SCLX 3
- Target Price
- DYAI $6.00
- SCLX $367.50
- AVG Volume (30 Days)
- DYAI 124.7K
- SCLX 248.0K
- Earning Date
- DYAI 08-13-2025
- SCLX 08-13-2025
- Dividend Yield
- DYAI N/A
- SCLX N/A
- EPS Growth
- DYAI N/A
- SCLX N/A
- EPS
- DYAI N/A
- SCLX N/A
- Revenue
- DYAI $4,135,078.00
- SCLX $44,236,000.00
- Revenue This Year
- DYAI $34.23
- SCLX $89.26
- Revenue Next Year
- DYAI $19.57
- SCLX $203.95
- P/E Ratio
- DYAI N/A
- SCLX N/A
- Revenue Growth
- DYAI 129.20
- SCLX N/A
- 52 Week Low
- DYAI $0.71
- SCLX $3.60
- 52 Week High
- DYAI $2.20
- SCLX $42.53
- Technical
- Relative Strength Index (RSI)
- DYAI 55.15
- SCLX 56.44
- Support Level
- DYAI $0.76
- SCLX $17.35
- Resistance Level
- DYAI $0.98
- SCLX $19.73
- Average True Range (ATR)
- DYAI 0.07
- SCLX 2.03
- MACD
- DYAI 0.02
- SCLX -0.40
- Stochastic Oscillator
- DYAI 89.52
- SCLX 27.97
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.